Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

May

15

TriSalus Reports Q1 2024 Financial Results and Business Update

DENVER–(BUSINESS WIRE)–May 15, 2024– TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results...

1

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

DENVER & SALT LAKE CITY–(BUSINESS WIRE)–Apr. 1, 2024– TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its...

27

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

– New safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced...

11

TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results

DENVER–(BUSINESS WIRE)–Mar. 11, 2024– TriSalus Life Sciences® Inc. (Nasdaq: TLSI) announced today that the Company will host...

7

TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101

– Nelitolimod, a class C TLR-9 agonist formerly called SD-101, is the Company’s therapeutic candidate...

14

TriSalus Life Sciences Announces CMS Reimbursement for the TriNav® Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code

DENVER–(BUSINESS WIRE)–TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology...

14

TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update

Completed merger with MedTech Acquisition Corporation (MTAC) and started public trading August 11th Reported 3Q23 revenues of $5.2...

7

TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call

Call Scheduled for Tuesday, November 14, 2023, at 9:00 a.m. ET DENVER–(BUSINESS WIRE)–Nov. 7, 2023– TriSalus Life...

4

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the...

3

TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

New data from PERIO-03 clinical trial indicates PEDD™ method resulted in modulation of the...

25

TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at SITC Annual Meeting

DENVER–(BUSINESS WIRE)–Oct. 25, 2023– TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel...

6

TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics

Devlin Brings Significant Expertise in Commercialization, Sales and Marketing DENVER–(BUSINESS WIRE)–Sep. 6, 2023– TriSalus...

Recent developments

News

May

15

TriSalus Reports Q1 2024 Financial Results and Business Update

April

1

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

March

27

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

March

11

TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results

March

7

TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101

December

14

TriSalus Life Sciences Announces CMS Reimbursement for the TriNav® Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code

November

14

TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update

November

7

TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call

November

4

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

November

3

TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

October

25

TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at SITC Annual Meeting

September

6

TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics